Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45739Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 沈立言 | |
| dc.contributor.author | Ting-Ju Chen | en |
| dc.contributor.author | 陳廷茹 | zh_TW |
| dc.date.accessioned | 2021-06-15T04:45:21Z | - |
| dc.date.available | 2010-08-10 | |
| dc.date.copyright | 2010-08-10 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-08-06 | |
| dc.identifier.citation | 行政院衛生署。2009。民國97年國人十大死因。http://www.doh.gov.tw/CHT2006/index_populace.aspx。
宋瑞樓、陳定信、廖運範。2006。肝炎肝硬化與肝癌。橘井文化事業股份有限公司。34-52頁。 周筱胤。2007。建立乙醯胺基苯酚誘導小鼠肝炎損傷模式與探討大棗對於小鼠肝損傷之護肝功效。台灣大學食品科技研究所碩士論文。 邱顯喬。2007。建立乙醯胺基苯酚誘導小鼠乾損傷模式並以此模式探討大蒜精油護肝功效。台灣大學食品科技研究所碩士論文。 胡芳晴。2008。評估乙醯胺基苯酚誘導慢性肝損傷之動物模式並以此探討七層塔精油之護肝功效。台灣大學食品科技研究所碩士論文。 紀瑋婷。2008。應用乙醯胺基苯酚誘導慢性肝炎損傷之動物模式探討薑精油與薑乙醇萃取物之護肝功效。台灣大學食品科技研究所碩士論文。 野村喜重郎。2007。肝病。世茂出版社。3-32頁。 陳健弘。2005。找回健康肝。原水文化。45-63頁。 Aruoma, O.I., Halliwell, B., Hoey, B.M., Butler, J., 1989. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6, 593-597. Ayonrinde, O.T., Phelps, G.J., Hurley, J.C., Ayonrinde, O.A., 2005. Paracetamol overdose and hepatotoxicity at a regional Australian hospital: a 4-year experience. Intern Med J 35, 655-660. Bellomo, G.; Mirabelli, F.; Dimonte, D.; Richelmi, P.; Thor, H.; Orrenius, C.; Orrenius, S., 1987. Formation and reduction of glutathioneprotein mixed disulfides during oxidative stress. Biochem. Pharmncol 36, 1313-1320. Benzie, I.F., 2003. Evolution of dietary antioxidants. Comp Biochem Physiol A Mol Integr Physiol 136, 113-126. Boigk, G., Stroedter, L., Herbst, H., Waldschmidt, J., Riecken, E.O., Schuppan, D., 1997. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26, 643-649. Chun, L.J., Tong, M.J., Busuttil, R.W., Hiatt, J.R., 2009. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 43, 342-349. Cotgreave, I.A., 1997. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 38, 205-227. Crocenzi, F.A., Roma, M.G., 2006. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr Med Chem 13, 1055-1074. Cunningham D.J., Robinson A., 1918. Cunningham's text-book of anatomy. W. Wood and company, 1187-1199. Davidson, D.G., Eastham, W.N., 1966. Acute liver necrosis following overdose of paracetamol. Br Med J 2, 497-499. De Flora, S., Bennicelli, C., Camoirano, A., Serra, D., Romano, M., Rossi, G.A., Morelli, A., De Flora, A., 1985. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. Carcinogenesis 6, 1735-1745. De Rosa, S.C., Zaretsky, M.D., Dubs, J.G., Roederer, M., Anderson, M., Green, A., Mitra, D., Watanabe, N., Nakamura, H., Tjioe, I., Deresinski, S.C., Moore, W.A., Ela, S.W., Parks, D., Herzenberg, L.A., 2000. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 30, 915-929. De Vries, N., De Flora, S., 1993. N-acetyl-l-cysteine. J Cell Biochem Suppl 17F, 270-277. Demir, S., Inal-Erden, M., 1998. Pentoxifylline and N-acetylcysteine in hepatic ischemia/reperfusion injury. Clin Chim Acta 275, 127-135. Dong, H., Haining, R.L., Thummel, K.E., Rettie, A.E., Nelson, S.D., 2000. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos 28, 1397-1400. Duhamel, R.C., Meezan, E., Brendel, K., 1981. The addition of SDS to the Bradford dye-binding protein assay, a modification with increased sensitivity to collagen. J Biochem Biophys Methods 5, 67-74. Eyer, P., Podhradsky, D., 1986. Evaluation of the micromethod for determination of glutathione using enzymatic cycling and Ellman's reagent. Anal Biochem 153, 57-66. Feher, J., Deak, G., Muzes, G., Lang, I., Niederland, V., Nekam, K., Karteszi, M., 1989. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]. Orv Hetil 130, 2723-2727. Feher, J., Lengyel, G., 2008. [Silymarin in the treatment of chronic liver diseases: past and future]. Orv Hetil 149, 2413-2418. Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W., Schneider, B., 1989. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9, 105-113. Flora, K., Hahn, M., Rosen, H., Benner, K., 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93, 139-143. Franco, R., Cidlowski, J.A., 2009. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 16, 1303-1314. Gazak, R., Svobodova, A., Psotova, J., Sedmera, P., Prikrylova, V., Walterova, D., Kren, V., 2004. Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 12, 5677-5687. Goldfrank L. R., Flomenbaum N., 2006. Goldfrank's toxicologic emergencies. McGraw-Hill Professional, 523-537. Hammond, C.L., Lee, T.K., Ballatori, N., 2001. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J Hepatol 34, 946-954. Hinson, J.A., Roberts, D.W., James, L.P., 2010. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol, 369-405. Johansson, L.H., Borg, L.A., 1988. A spectrophotometric method for determination of catalase activity in small tissue samples. Anal Biochem 174, 331-336. Kelly, G.S., 1998. Clinical applications of N-acetylcysteine. Altern Med Rev 3, 114-127. Langley, S.C., Kelly, F.J., 1992. Differing response of the glutathione system to fasting in neonatal and adult guinea pigs. Biochem Pharmacol 44, 1489-1494. Larsen, L.C., Fuller, S.H., 1996. Management of acetaminophen toxicity. Am Fam Physician 53, 185-190. Larson, A.M., 2007. Acetaminophen hepatotoxicity. Clin Liver Dis 11, 525-548, vi. Larson, A.M., Polson, J., Fontana, R.J., Davern, T.J., Lalani, E., Hynan, L.S., Reisch, J.S., Schiodt, F.V., Ostapowicz, G., Shakil, A.O., Lee, W.M., 2005. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42, 1364-1372. Lenart, J., Dombrowski, F., Gorlach, A., Kietzmann, T., 2007. Deficiency of manganese superoxide dismutase in hepatocytes disrupts zonated gene expression in mouse liver. Arch Biochem Biophys 462, 238-244. Letteron, P., Labbe, G., Degott, C., Berson, A., Fromenty, B., Delaforge, M., Larrey, D., Pessayre, D., 1990. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol 39, 2027-2034. Maddrey, W.C., 2005. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 39, S83-89. Marklund, S., 1980. Distribution of CuZn superoxide dismutase and Mn superoxide dismutase in human tissues and extracellular fluids. Acta Physiol Scand Suppl 492, 19-23. Mannervik, B., Alin, P., Guthenberg, C., Jensson, H., Tahir, M.K., Warholm, M., Jornvall, H., 1985. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 82, 7202-7206. Mayer, K.E., Myers, R.P., Lee, S.S., 2005. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 12, 559-567. McKay, A., Cassidy, D., Sutherland, F., Dixon, E., 2008. Clinical results of N-acetylcysteine after major hepatic surgery: a review. J Hepatobiliary Pancreat Surg 15, 473-478. Nakata, K., Kawase, M., Ogino, S., Kinoshita, C., Murata, H., Sakaue, T., Ogata, K., Ohmori, S., 1996. Effects of age on levels of cysteine, glutathione and related enzyme activities in livers of mice and rats and an attempt to replenish hepatic glutathione level of mouse with cysteine derivatives. Mech Ageing Dev 90, 195-207. Neal M. J., 2005. Medical pharmacology at a glance. Wiley-Blackwell, 14-15. Ohkawa, H., Ohishi, N., Yagi, K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95, 351-358. Ostapowicz, G., Fontana, R.J., Schiodt, F.V., Larson, A., Davern, T.J., Han, S.H., McCashland, T.M., Shakil, A.O., Hay, J.E., Hynan, L., Crippin, J.S., Blei, A.T., Samuel, G., Reisch, J., Lee, W.M., 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137, 947-954. Pepping, J., 1999. Milk thistle: Silybum marianum. Am J Health Syst Pharm 56, 1195-1197. Raucy, J.L., Lasker, J.M., Lieber, C.S., Black, M., 1989. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 271, 270-283. Rochling, F.A., 2001. Evaluation of abnormal liver tests. Clinical Cornerstone 3, 1-12. Scheibmeir, H.D., Christensen, K., Whitaker, S.H., Jegaethesan, J., Clancy, R., Pierce, J.D., 2005. A review of free radicals and antioxidants for critical care nurses. Intensive Crit Care Nurs 21, 24-28. Schueler, L., Harper, J.L., 1995. Acetaminophen toxicity: report of case and review of the literature. J Oral Maxillofac Surg 53, 1208-1212. Shayiq, R.M., Roberts, D.W., Rothstein, K., Snawder, J.E., Benson, W., Ma, X., Black, M., 1999. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology 29, 451-463. Sonnenbichler, J., Scalera, F., Sonnenbichler, I., Weyhenmeyer, R., 1999. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 290, 1375-1383. Steven I. B., Harry S., 1997. Oxidants, antioxidants, and free radicals. CRC Press, 28-29. Sturgill, M.G., Lambert, G.H., 1997. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Clin Chem 43, 1512-1526. Sullivan J.B., Krieger G.R., 2001. Clinical environmental health and toxic exposures. Lippincott Williams & Wilkins, 235-236. Tanaka, E., Yamazaki, K., Misawa, S., 2000. Update: the clinical importance of acetaminophen hepatotoxicity in non-alcoholic and alcoholic subjects. J Clin Pharm Ther 25, 325-332. Thummel, K.E., Lee, C.A., Kunze, K.L., Nelson, S.D., Slattery, J.T., 1993. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 45, 1563-1569. Wiseman, H., Halliwell, B., 1996. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313 ( Pt 1), 17-29. Zhao, T., Singhal, S.S., Piper, J.T., Cheng, J., Pandya, U., Clark-Wronski, J., Awasthi, S., Awasthi, Y.C., 1999. The role of human glutathione S-transferases hGSTA1-1 and hGSTA2-2 in protection against oxidative stress. Arch Biochem Biophys 367, 216-224. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45739 | - |
| dc.description.abstract | 慢性肝病及肝硬化在台灣一直是很嚴重的問題，在衛生署2009年統計資料中，肝癌為2008年國人癌症十大死亡率的第二名，其他相關肝臟疾病也為十大死因之一，因此保護肝臟及抑制肝癌的議題就特別受到社會大眾的重視。近年來護肝保健食品發展快速，故建立一套標準的護肝功效之保健食品評估方法就特別重要。衛生署頒訂「以四氯化碳誘發大(小)白鼠慢性肝損傷實驗模式」為目前健康食品護肝功效作用之動物模式評估方法，然而四氯化碳為管制化學物質，一般生活中也不易接觸。乙醯胺基苯酚 (acetaminophen, APAP) 為一般常見解熱鎮痛劑的主要成分，當食用過量易產生肝腎損傷，因此本實驗欲建立APAP誘導肝損傷之護肝效果評估之動物模式，將有助於健康食品之開發。本實驗以BALB/c小鼠作為實驗品系，探討不同性別對APAP誘導肝損傷之影響，並評估具有抗氧化能力的半胱胺酸醋酸酯 (N-acetylcysteine, NAC) 及乳薊 (Silybum marianum) 萃取物–水飛薊素 (Silymarin) 作為正對照組之可行性。Silymarin在過去臨床上常用來作為抑制肝損傷之藥物，在四氯化碳誘發大鼠或小鼠慢性肝損傷實驗模式中更被視為正對照組的使用藥物，而NAC在臨床上則常被用為APAP急性中毒的解毒藥物。在急性實驗中 (給予一次APAP誘導) 發現，母鼠對於APAP的誘導所造成血液中AST及ALT值較公鼠高出20倍，由此可知母鼠對於APAP耐受性不如公鼠，因此後續均使用公鼠來進行實驗。在APAP誘導急性肝損傷模式中，BALB/c公鼠先給予NAC或Silymarine 連續七日，再以600 mg APAP/kg bw進行急性肝損傷誘導，藉此觀察NAC及Silymarin對抑制急性肝損傷的效果。病理組織切片觀察及血液生化值 (AST、ALT) 分析結果顯示，相較負對照組APAP誘導，NAC處理組 (600、1200 mg/kg bw) 明顯改善APAP誘導所造成之肝損傷，但是Silymarin (50~280 mg/kg bw) 處理組的保護效果皆不及NAC，因此後續為期八週之慢性實驗便不再使用Silymarin進行評估。由NAC處理組之慢性實驗結果發現，血液生化指標 (ALT及AST)、肝臟脂質過氧化、病理組織切片、肝臟抗氧化物質 (GSH、GST) 及抗氧化酵素結果顯示，與僅以APAP誘導肝損傷的負對照組相比較下，給予NAC (600、1200 mg /kg bw) 之處理組可明顯改善因APAP誘導之肝損傷現象，但因兩組NAC處理組間則無顯著差異，因此600 mg NAC/kg bw可作為APAP誘導肝損傷試驗之較佳正對照組劑量。綜合上述實驗結果，以BALB/c公小鼠進行APAP誘導慢性肝損傷，並以600 mg NAC/kg bw為正對照組，以進行保健食品之護肝功效評估，應可作為評估健康食品之護肝保健功效之另一動物模式的選擇。 | zh_TW |
| dc.description.abstract | According to the report of Department of Health of Taiwan in 2009, chronic liver disease and cirrhosis are the eighth and the tenth leading causs of death, respectively, and liver cancer is the second leading cancer-caused deaths. Therefore, how to mentain liver health is a very important topic in Taiwan. Nowadays, the model of carbon tetrachloride (CCl4)-induced hepatotoxicity is used to evaluate the hepatoprotective effect of on health food. However, CCl4 is recognized as a damge materia and controlled seriously by the government in Taiwan. Acetaminophen (APAP) is a clinically analgesic and antipyretic drug. Previous researches demoustrated that APAP causes liver injury in experimental animals and human being. The aim of this study was to establish an appropriate model of APAP-induced liver injury, and to evaluate the liver protective effects of N-acetylcysteine (NAC) and Silymarin in BALB/c mice. In the acute experiment, the results showed that APAP increased the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (>15000 IU/L) in female mice much more than those (500-1000 IU/L) in male mice after APAP intraperitoneal injection. The death rate in female mice (83%) is higher than that (17%) in male ones. It suggested that female mice were not suitable to be used for the experiments. Additionally, male BALB/c mice with APAP- induced liver injury took NAC and Silymarin once daily for 7 days. The results showed that NAC at 600 and 1200 mg/kg bw decreased ALT and AST values in BALB/c mice with APAP-induced hepatotoxicity. The hepatoprotective effect of NAC was also confirmed using histopathological examination of the liver. The date showed that hepatoprotective effect of NAC was better than that of Silymarin. Furthermore, male BALB/c mice were given with NAC once daily on APAP- induced the chronic experiment. It suggested that NAC at 600 and 1200 mg/kg bw effectively improved the APAP-induced liver injury in BALB/c mice. Therefore, these results showed that NAC (600 mg/kg bw) is better to be positive control in both acute and chronic APAP-induced liver injury in BALB/c mice for evaluation of the heptoprotective effect of health food. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T04:45:21Z (GMT). No. of bitstreams: 1 ntu-99-R97641008-1.pdf: 13589644 bytes, checksum: e632834223439d169e0e71df647c1b76 (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 中文摘要 I
英文摘要 III 圖次 VII 表次 IX 縮寫表 XII 第一章、前言 1 第二章、文獻回顧 3 第一節、肝臟 3 一、生理構造 3 二、肝臟解毒代謝路徑 8 三、肝病種類 11 四、 肝臟疾病的自覺症狀 13 五、肝指數 13 第二節、乙醯胺基苯酚 (N-acetyl-p-aminophenol, APAP) 15 一、基本介紹 15 二、乙醯胺基苯酚造成肝損傷之機制 16 三、乙醯胺基苯酚毒性所引起肝細胞之氧化壓力及粒線體失能 18 第三節、半胱胺酸醋酸酯 (N-acetylcysteine, NAC) 19 一、基本介紹 19 二、NAC解毒功效 20 三、劑量使用 20 第四節、乳薊 (Milk Thistle) 萃取物–水飛薊素 (Silymarin)23 一、乳薊的歷史 23 二、Silymarin 藥理作用 23 三、Silymarin 安全性 24 四、Silymarin於肝損傷方面應用 24 第五節、抗氧化機制 27 一、ROS（活性氧屬，reactive oxygen species）介紹 27 二、人體內生的抗氧化作用 28 第三章、實驗架構 30 一、實驗整體架構 30 二、評估APAP誘導BALB/c小鼠急性肝損傷之性別差異 31 三、比較NAC 和Silymarin 對APAP誘導BALB/c公鼠急性肝損傷之保護效果 32 四、評估不同劑量Silymarin 對APAP誘導BALB/c公鼠急性肝損傷之保護效果 33 五、評估NAC 對APAP誘導BALB/c公鼠慢性肝損傷之保護效果 34 第四章、材料與方法 35 第一節、實驗材料 35 一、實驗藥品 35 二、實驗儀器 35 第二節、實驗方法 36 一、 實驗動物飼養 36 二、 APAP劑量及實驗動物篩選 36 三、NAC 和 Silymarin劑量篩選 37 第三節、實驗設計 38 一、評估APAP誘導BALB/c小鼠急性肝損傷之性別差異 38 二、 比較NAC 和Silymarin 對APAP誘導BALB/c公鼠急性肝損傷之保護效果 39 三、評估Silymarin 對APAP誘導BALB/c公鼠急性肝損傷之保護效果40 四、評估NAC 對APAP誘導BALB/c公鼠慢性肝損傷之保護效果 41 第四節、實驗原理 42 一、血液生化值測定 42 二、肝臟測定 43 三、肝組織病理觀察 48 四、統計方法 49 第五章、結果 50 一、評估APAP誘導BALB/c小鼠急性肝損傷之性別差異 50 二、比較NAC和Silymarin對APAP誘導BALB/c公鼠急性肝損傷之保護效果 51 三、評估Silymarin對APAP誘導BALB/c公鼠急性肝損傷之保護效果 53 四、評估NAC對APAP誘導BALB/c公鼠慢性肝損傷之保護效果 55 第六章、討論 61 一、BALB/c小鼠性別差異對APAP誘導肝損傷之影響 61 二、正對照組藥物護肝效果之評估 61 第七章、結論 66 實驗結果及圖表 67 文獻 93 | |
| dc.language.iso | zh-TW | |
| dc.subject | 健康食品 | zh_TW |
| dc.subject | 乙醯胺基苯酚 | zh_TW |
| dc.subject | 半胱胺酸醋酸酯 | zh_TW |
| dc.subject | 乳薊 | zh_TW |
| dc.subject | 護肝功效 | zh_TW |
| dc.subject | N-acetylcysteine | en |
| dc.subject | health food | en |
| dc.subject | liver protective effect | en |
| dc.subject | Silymarin | en |
| dc.subject | acetaminophen | en |
| dc.title | 建立乙醯胺基苯酚誘導BALB/c小鼠肝損傷動物模式及探討較佳正對照組之藥品 | zh_TW |
| dc.title | Evaluation of APAP-induced hepatotoxicity in BALB/c mice and selection of the suitable drug as positive control | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 邱智賢,鍾景光,李宗貴 | |
| dc.subject.keyword | 乙醯胺基苯酚,半胱胺酸醋酸酯,乳薊,護肝功效,健康食品, | zh_TW |
| dc.subject.keyword | acetaminophen,N-acetylcysteine,Silymarin,liver protective effect,health food, | en |
| dc.relation.page | 117 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2010-08-06 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 食品科技研究所 | zh_TW |
| Appears in Collections: | 食品科技研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-99-1.pdf Restricted Access | 13.27 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.